Syneos Health to Present Actionable Commercial Insights Designed for Biopharmaceutical Companies at BIO International Convention
“Biopharmaceutical companies are facing mounting pressure to deliver profitable growth for investors, while speeding game-changing therapies to patients, in an environment of increasing scrutiny,” said
Dealmakers’ Intentions: 2018 Market Outlook
As large biopharmaceutical companies prune their portfolios and consider repatriation options, the expectation is running higher than ever for an uptick in M&A this year. The tension for CEOs in this environment is delivering a confident story about achieving profitable growth for investors while facing an increasingly complex marketplace. Join a highly distinguished panel of dealmakers who will explore the impact these market forces will have on biopharmaceutical companies as they strive to make the next big deal.
Moderator Neel Patel, Managing Director, Commercial Strategy & Planning at
Communicating Value Through the Eye of the Beholder
Value is in the eye of the beholder. Yet, the value of game-changing medicines is coming under greater scrutiny in the U.S. marketplace more than ever before. Companies are spending years developing drugs, only to arrive at commercialization disconnects with the very audiences they seek to serve. A well-defined value proposition for payers is no longer sufficient. Increasingly, developers must foster shared stakeholder expectations about the value of new medicines far sooner on the runway to commercialization.
|Investor Relations Contact:||Press/Media Contact:|
|Ronnie Speight||Danielle DeForge|
|Vice President, Investor Relations||Senior Director, External Communications|
|+1 919 745 2745||+1 202 210 5992|
Source: Syneos Health